Find Clinical Trial

Phase I, open label, dose-escalation study to evaluate the safety, expansion, persistence and biological activity of a single dose of UCART19 (allogeneic engineered T-cells expressing anti-CD19 chimeric antigen receptor), administered intravenously in patients with relapsed or refractory CD19 positive B-cell acute lymphoblastic leukaemia (B-ALL). – CALM study


← Back
Study Phase

Phase 1

Therapeutic Area

Cancers

Active substance/
Medical device

UCART19, S068587

SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS068587
Protocol CodeCL1-68587-002
EudraCT Code2016-000296-24
NCT CodeNCT02746952


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.
Accessibility